Conference abstract · 27 Oct 2014
Conference abstractPublished 10 Aug 2017
Considerations in biosimilars commercialization
Merck Group, Switzerland
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The biosimilar market holds significant potential and benefit for all stakeholders. The experience with first wave of biosimilar launches provide interesting and in some cases exciting references for the next wave of more complex biosimilars. What does experience in Europe and US could show us so far about the evolving opportunity in biosimilars? In this talk the challenges and opportunities with commercialization of biosimilars will also be covered.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 23 Sep 2013
Commercialization considerations for biosimilars
Conference abstract · 4 Apr 2024
Understanding the commercial value of Biosimilars: Learning from launches in EU and US
Conference abstract · 16 Sep 2020
Challenges With Successful Commercialization Of Biosimilars
Editorial · 13 May 2019
Pharma Sci-Commercializing Biosimilars: Challenges, New Strategies and Finding Path to Success- Prashant A Pandya-Reliance Lifesciences
More from this journal
The newest in Journal of Bioanalysis & Biomedicine.
Article · 29 Dec 2025
Label-Free Biosensing: Revolutionizing Disease Detection and Drug Discovery
Article · 29 Dec 2025
Epigenetic Modifications: Bioanalysis for Disease and Therapeutics
Article · 29 Dec 2025
Advancing Bioanalysis: New Tech, AI, and Precision Medicine
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioanalysis & Biomedicine
- BylineArticles whose byline prints “Darius Panaligan”

